Patent: 9,150,531
✉ Email this page to a colleague
Summary for Patent: 9,150,531
Title: | Tricyclic lactones for treatment of cancer |
Abstract: | The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-.kappa.B signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed. |
Inventor(s): | Gidlof; Ritha (Lund, SE), Johansson; Martin (Heberg, SE), Sterner; Olov (Malmo, SE), Munoz; Eduardo (Cordova, ES) |
Assignee: | Glactone Pharma Development AB (Helsingborg, SE) |
Application Number: | 13/811,015 |
Patent Claims: | see list of patent claims |
Details for Patent 9,150,531
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2030-07-19 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 02/20/1991 | ⤷ Try a Trial | 2030-07-19 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 06/28/2000 | ⤷ Try a Trial | 2030-07-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |